A Phase 1b/2 Study of Talquetamab and Teclistamab in People With Multiple Myeloma


Full Title

A Phase 1b/2 Dose Escalation and Expansion Study of the Combination of the Bispecific T Cell Redirection Antibodies Talquetamab and Teclistamab in Participants with Relapsed or Refractory Multiple Myeloma


Researchers want to see if using the drugs talquetamab and teclistamab is helpful for treating people with multiple myeloma. The people in this study have multiple myeloma that keeps growing even after treatment. In addition, their cancer has formed tumors outside the bone marrow, in the soft tissues or organs of the body. This is called extramedullary disease.

Talquetamab and teclistamab help the immune system find and attack multiple myeloma cells. Both drugs are given as injections under the skin.

Who Can Join

To join this study, there are a few conditions. You must:

  • Have extramedullary multiple myeloma that came back or keeps growing even with treatment.
  • Have recovered from the serious side effects of previous treatments before getting talquetamab and teclistamab.
  • Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
  • Be age 18 or older.


For more information or to see if you can join this study, please call Dr. Saad Usmani’s office at 646-608-4165.




Phase I/II (phases 1 and 2 combined)

Disease Status

Relapsed or Refractory



ClinicalTrials.gov ID